140 related articles for article (PubMed ID: 32546962)
1. Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets.
Hwang JG; Yu KS; Lee S
Drug Des Devel Ther; 2020; 14():1953-1961. PubMed ID: 32546962
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects.
Kang WY; Seong SJ; Ohk B; Gwon MR; Kim BK; Cho S; Shim WS; Lee KT; Kim EH; Yang DH; Lee HW; Yoon YR
Drug Des Devel Ther; 2018; 12():3607-3615. PubMed ID: 30464392
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects.
Oh M; Ghim JL; Park SE; Kim EY; Shin JG
Drug Des Devel Ther; 2018; 12():1157-1164. PubMed ID: 29780236
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.
Choi Y; Lee S; Jang IJ; Yu KS
Drug Des Devel Ther; 2018; 12():2301-2309. PubMed ID: 30087555
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.
Lee J; Rhee SJ; Lee S; Yu KS
Drug Des Devel Ther; 2018; 12():787-794. PubMed ID: 29670335
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants.
Kim JH; Song JH; Kim M; Hong JH; Sunwoo J; Jung JG
Adv Ther; 2024 Jul; 41(7):2808-2825. PubMed ID: 38771476
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic comparison between fixed-dose combination of fimasartan/amlodipine 60/10 mg and the corresponding loose combination through partial replicated crossover study in healthy subjects.
Yang E; Lee S; Lee H; Hwang I; Jang IJ; Yu KS; Lee S
Transl Clin Pharmacol; 2019 Dec; 27(4):134-140. PubMed ID: 32095481
[TBL] [Abstract][Full Text] [Related]
8. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
Kang WY; Lee HW; Gwon MR; Cho S; Shim WS; Lee KT; Yang DH; Seong SJ; Yoon YR
Drug Des Devel Ther; 2020; 14():2101-2111. PubMed ID: 32546973
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects.
Jung J; Lee S; Oh J; Lee S; Jang IJ; Lee D; Yu KS
Transl Clin Pharmacol; 2021 Mar; 29(1):53-64. PubMed ID: 33855001
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects.
Khwarg J; Lee S; Jang IJ; Kang WH; Lee HJ; Kim KY; Jeong KS; Won C; Choi YW; Ha DC; Jung R; Han MG; Jung WT; Nam KY; Kim Y; Yu KS; Oh J
Drug Des Devel Ther; 2024; 18():395-406. PubMed ID: 38352172
[TBL] [Abstract][Full Text] [Related]
11. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
14. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
15. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
[TBL] [Abstract][Full Text] [Related]
16. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
[TBL] [Abstract][Full Text] [Related]
18. The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan.
Gu N; Cho JY; Shin KH; Jang IJ; Rhee MY
Drug Des Devel Ther; 2016; 10():1525-31. PubMed ID: 27143858
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
Kang WY; Kim EH; Seong SJ; Gwon MR; Yang DH; Kim HJ; Lim MS; Lee HW; Yoon YR
Int J Clin Pharmacol Ther; 2016 Dec; 54(12):992-1003. PubMed ID: 27668695
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets.
Ghim JL; Phuong NTT; Kim MJ; Kim EJ; Song GS; Ahn S; Shin JG; Kim EY
Drug Des Devel Ther; 2019; 13():1623-1632. PubMed ID: 31190741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
